Shares of ImmuPharma plc (LON:IMM – Get Free Report) rose 4.9% on Friday . The company traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.04). Approximately 109,382,164 shares traded hands during mid-day trading, an increase of 245% from the average daily volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Price Performance
The company has a 50-day moving average of GBX 1.44 and a 200 day moving average of GBX 1.65. The company has a market cap of £15.30 million, a PE ratio of -367.30 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- Insider Trading – What You Need to Know
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
